We are live on ! Find out more
HAE icon

Haemonetics

292 hedge funds and large institutions have $5.92B invested in Haemonetics in 2018 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 71 increasing their positions, 146 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more capital invested

Capital invested by funds: $4.52B → $5.92B (+$1.41B)

3.58% more ownership

Funds ownership: 96.47%100.06% (+3.6%)

4% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 49

0% less funds holding

Funds holding: 293292 (-1)

21% less call options, than puts

Call options by funds: $3.42M | Put options by funds: $4.35M

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

51% less repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 146

Holders
292
Holders Change
-1
Holders Change %
-0.34%
% of All Funds
6.68%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
51
Increased
71
Reduced
146
Closed
49
Calls
$3.42M
Puts
$4.35M
Net Calls
-$929K
Net Calls Change
+$13.1M

HAE Hedge Fund Activity: Q3 2018 in Review

292 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2018, worth a combined $5.92B — up 31% from $4.52B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new HAE positions and 49 closed out — a net gain of 2 holders — while 71 added to existing stakes and 146 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $267M. The largest seller was Nitorum Capital, cutting an estimated $41.2M.

  • 292 institutional investors held Haemonetics (HAE) as of Q3 2018, down from 293 in Q2 2018.
  • Funds reported $5.92B of Haemonetics stock for Q3 2018, up 31% quarter-over-quarter.
  • 51 funds opened new Haemonetics positions in Q3 2018 and 49 closed out, a net change of +2 holders.
  • The largest Haemonetics buyer in Q3 2018 was Wellington Management Group, an estimated $267M added.
  • The largest Haemonetics seller in Q3 2018 was Nitorum Capital, an estimated $41.2M sold.

Based on aggregated 13F filings for Q3 2018.